trending Market Intelligence /marketintelligence/en/news-insights/trending/r1yymntvm_h__zuv1t9h2g2 content esgSubNav
In This List

Novo Nordisk's Ozempic approved in Japan

Blog

Insight Weekly: Recession risk persists; Banks pull back from crypto; 2022 laggard stocks rally

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Blog

Insight Weekly: Inflation eases; bank M&A slows; top companies boost market share

Blog

Insight Weekly: PE firms shift strategies; bank earnings kick off; bankruptcies plummet


Novo Nordisk's Ozempic approved in Japan

The Japanese Ministry of Health, Labor and Welfare approved Novo Nordisk A/S' Ozempic to treat adults with type 2 diabetes.

The approval was based on results from the company's clinical trial program called Sustain, which enrolled more than 8,000 patients in five studies. Data showed that Ozempic reduced blood sugar levels better than comparator treatments and led to greater reductions in mean body weight compared to placebo.

Denmark-based Novo Nordisk plans to launch the drug in Japan within the coming months.

Ozempic is already approved in the U.S., Canada and the EU.